Search research articles
Contact Us
Filters
Showing results (51-60 of 63) with videos related to
Page
of 7
Sort By:
Nephron
|
January 1, 1985
Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis
M K Chan, A K Browning, C J Poole, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2005
A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG)
N S Reed, C J Poole, R Coleman, et al.
Cell Death and Differentiation
|
February 23, 2002
Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells
A E Milner, D H Palmer, E A Hodgkin, et al.
International Journal of Oncology
|
June 4, 1998
A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma
L W Seymour, S P Olliff, C J Poole, et al.
British Journal of Cancer
|
July 31, 2008
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation
A M Wardley, L Hiller, H C Howard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2001
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer
C J Poole, T Perren, A Burton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2012
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
S B Kaye, C J Poole, A Dańska-Bidzińska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 22, 2015
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H R Ali, S-E Glont, F M Blows, et al.
British Journal of Cancer
|
January 11, 2007
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
S A Hussain, R Ganesan, G Reynolds, et al.
British Journal of Cancer
|
September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life
H M Earl, L Hiller, J A Dunn, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 63) with videos related to
Sort By:
Page
of 7
Nephron
|
January 1, 1985
Cefuroxime pharmacokinetics in continuous and intermittent peritoneal dialysis
M K Chan, A K Browning, C J Poole, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2005
A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: a study by the Scottish Gynaecological Cancer Trials Group (SGCTG)
N S Reed, C J Poole, R Coleman, et al.
Cell Death and Differentiation
|
February 23, 2002
Induction of apoptosis by chemotherapeutic drugs: the role of FADD in activation of caspase-8 and synergy with death receptor ligands in ovarian carcinoma cells
A E Milner, D H Palmer, E A Hodgkin, et al.
International Journal of Oncology
|
June 4, 1998
A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma
L W Seymour, S P Olliff, C J Poole, et al.
British Journal of Cancer
|
July 31, 2008
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation
A M Wardley, L Hiller, H C Howard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 24, 2001
Phase II clinical trials of cisplatin-then-paclitaxel and paclitaxel-then-cisplatin in patients with previously untreated advanced epithelial ovarian cancer
C J Poole, T Perren, A Burton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 25, 2012
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
S B Kaye, C J Poole, A Dańska-Bidzińska, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 22, 2015
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes
H R Ali, S-E Glont, F M Blows, et al.
British Journal of Cancer
|
January 11, 2007
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
S A Hussain, R Ganesan, G Reynolds, et al.
British Journal of Cancer
|
September 18, 2008
NEAT: National Epirubicin Adjuvant Trial--toxicity, delivered dose intensity and quality of life
H M Earl, L Hiller, J A Dunn, et al.
Page
of 7